| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership change | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | Birkemeyer Elaine M. CHIEF FINANCIAL OFFICER | Sale | -4,631 | -3.43%130,188 | $24.49 | $113,404 | View SEC filing | |
| 2026-02-26 | Birkemeyer Elaine M. CHIEF FINANCIAL OFFICER | Sale | -7,701 | -5.40%134,819 | $28.94 | $222,880 | View SEC filing | |
| 2026-02-26 | Burns Kristie Sr. VP Mktg & Clinical Affairs | Sale | -6,246 | -7.03%82,581 | $28.94 | $180,764 | View SEC filing | |
| 2026-02-26 | Dodd Sheri Louise Chief Executive Officer | Sale | -10,993 | -4.31%243,885 | $28.94 | $318,144 | View SEC filing | |
| 2026-02-24 | Birkemeyer Elaine M. CHIEF FINANCIAL OFFICER | Sale | -5,518 | -3.73%142,520 | $28.30 | $156,144 | View SEC filing | |
| 2026-02-24 | Burns Kristie Sr. VP Mktg & Clinical Affairs | Sale | -4,439 | -4.76%88,827 | $28.30 | $125,612 | View SEC filing | |
| 2026-02-24 | Dodd Sheri Louise Chief Executive Officer | Sale | -15,240 | -5.64%254,878 | $28.30 | $431,245 | View SEC filing | |
| 2026-01-06 | Burns Kristie Sr. VP Mktg & Clinical Affairs | Sale | -5,139 | -6.63%72,401 | $28.85 | $148,260 | View SEC filing | |
| 2025-08-12 | Dodd Sheri Louise Chief Executive Officer | Sale | -7,762 | -4.28%173,479 | $12.36 | $95,907 | View SEC filing | |
| 2025-05-14 | Birkemeyer Elaine M. Chief Financial Officer | Sale | -2,921 | -2.86%99,111 | $9.94 | $29,037 | View SEC filing | |
| 2025-05-12 | Dodd Sheri Louise Chief Executive Officer | Sale | -3,149 | -1.71%181,241 | $9.83 | $30,955 | View SEC filing | |
| 2025-05-09 | BURKE WILLIAM W Director | Sale | -3,300 | -6.37%48,520 | $9.67 | $31,911 | View SEC filing | |
| 2025-02-27 | Birkemeyer Elaine M. Chief Financial Officer | Sale | -2,066 | -1.98%102,032 | $14.51 | $29,980 | View SEC filing | |
| 2025-02-27 | Burns Kristie Sr. VP Mktg & Clinical Affairs | Sale | -6,468 | -7.70%77,540 | $14.40 | $93,160 | View SEC filing | |
| 2025-02-27 | REUVERS DANIEL L. Director | Sale | -28,338 | -11.66%214,604 | $14.18 | $401,850 | View SEC filing | |
| 2025-02-24 | REUVERS DANIEL L. Director | Sale | -10,938 | -4.31%242,942 | $14.55 | $159,147 | View SEC filing | |
| 2025-02-24 | Burns Kristie Sr. VP Mktg & Clinical Affairs | Sale | -4,830 | -5.44%84,008 | $14.65 | $70,753 | View SEC filing | |
| 2025-02-24 | Birkemeyer Elaine M. Chief Financial Officer | Sale | -3,778 | -3.50%104,098 | $14.70 | $55,538 | View SEC filing | |
| 2024-08-14 | Ferstler Sherri Lee Senior VP, Sales | Sale | -1,550 | -3.84%38,764 | $13.07 | $20,263 | View SEC filing | |
| 2024-05-20 | Birkemeyer Elaine M. Chief Financial Officer | Sale | -3,041 | -4.73%61,295 | $13.68 | $41,590 | View SEC filing | |
| 2024-05-10 | BURKE WILLIAM W Director | Sale | -2,500 | -9.00%25,273 | $14.06 | $35,150 | View SEC filing | |
| 2024-05-08 | Burns Kristie Sr. VP Mktg & Clinical Affairs | Sale | -815 | -1.29%62,574 | $14.37 | $11,713 | View SEC filing | |
| 2024-02-29 | Burns Kristie Sr. VP Mktg & Clinical Affairs | Sale | -1,334 | -2.06%63,389 | $15.52 | $20,707 | View SEC filing | |
| 2024-02-29 | REUVERS DANIEL L. President and CEO | Sale | -6,085 | -2.49%238,027 | $15.52 | $94,437 | View SEC filing | |
| 2024-02-27 | REUVERS DANIEL L. President and CEO | Sale | -11,617 | +23.48%244,112 | $15.37 | $178,497 | View SEC filing |
1-25 of 267
